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ABSTRACT 
THE COST-EFFECTIVENESS OF THE KENTUCKY PILOT PROJECT OF 
ALLOWING PRIMARY PCI AT HOSPITALS WITHOUT ONSITE CABG 
CAPABILITIES 
Pedro G. Ramos 
November 23 rd, 2010 
A myocardial infarction (MI) occurs when blood supply to the heart is cut off by a 
blockage in one of the coronary arteries. Most hospitals treat a patient with thrombolysis 
or a percutaneous coronary intervention (PC I). The latter has been established as the 
preferred revascularization method. However, the American College of Cardiologists and 
the American Heart Association strongly recommend that a hospital performing PCI must 
also have coronary artery bypass graft capabilities (CABG). By following these 
recommendations, the state of Kentucky has limited the number of hospitals allowed to 
perform PCI and thereby limiting access to such a life-saving procedure. 
Recently, the state of Kentucky has begun evaluating if hospitals without such 
capabilities should be allowed to perform primary PCI, and data from this evaluation 
allowed the establishment of the medical soundness of allowing such hospitals to perform 
primary PCI. To have the most comprehensive understanding of the effects of allowing 
hospitals without surgical-backup performing primary PCI, the effects and costs must be 
evaluated simultaneously. The current study aims to 
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study the financial feasibility of allowing these hospitals to do emergency PCI in addition 
to hospitals with onsite open-heart surgery capabilities. 
The estimates have been derived from a systematic literature review of national 
studies based on PCI registries as well as our earlier study - KENTUCKY PILOT 
PROJECT FOR PRIMARY PCI WITHOUT ONSITE CABG. Costs estimates were 
derived from the National Inpatient Sample, which approximates a twenty percent sample 
of the U.S. community hospitals. In determining costs, the sample was extracted by 
filtering using ICD-9 codes. A deterministic model was developed so that more 
uncertainty would not be introduced. The economic evaluation focused on estimating the 
incremental cost effectiveness ratio (lCER) of allowing regional hospitals to perform 
primary PCI from a payer's perspective. Uncertainty about the model parameters was 
investigated through employing sensitivity analysis techniques. 
The study found that there were no statistically significant differences in 
outcomes between hospitals with and without CABG capabilities. The only 
characteristic, which was significantly different between these two groups, was total 
charges. The alternative to allow Regional Hospitals as well to perform primary PCI 
dominated the other alternative of Only Allowing Hospitals with Onsite CABG to perform 
PCl. That is, allowing regional hospitals to perform primary PCI both incur fewer costs 
while also averting more deaths. However, sensitivity to the cost of PC I at regional 
hospitals was observed in the model. The study suggests that by allowing primary PCI to 
be performed at selected facilities without onsite CABG, the state of Kentucky can 
expand access to PCI and reduce geographical health disparities, one of its main 
healthcare initiatives. 
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For individuals experiencing a myocardial infarction (MI), commonly 
referred to as a heart attack (1), a trip to an emergency department to have the 
blocked artery quickly opened by inflating a small balloon and inserting a tiny 
metal structure called a stent that acts as permanent scaffolding is lifesaving. In 
these emergency situations, the above procedure is termed primary 
Percutaneous Coronary Intervention (PCI) (2). This is contrasted to elective PCI 
in which PCI is performed prior to a heart attack. Restoring blood flow to the 
heart muscle as quickly as possible is truly a benefit to the patient. The American 
College of Cardiology, the American Heart Association and the Society for 
Cardiovascular Angiography and Interventions strongly recommend that primary 
PCI should only be performed in facilities that have an experienced 
cardiovascular surgical team available as emergency backup for all procedures 
(3). 
Recently, the State of Kentucky has begun evaluating if hospitals without 
such capabilities should be allowed to perform primary PCI. As a result, data 
from this evaluation allowed our research team to establish the medical 
soundness of allowing such hospitals to perform primary PCI (4); our results 
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suggest that hospitals without surgical backup capabilities achieved similar 
outcomes as hospitals with surgical backup capabilities for all studied outcomes 
(mortality, door-to-balloon time, cardiac arrests and emergency surgeries as a 
result of the PCI). However, in order for health interventions to be incorporated 
effectively, both the effectiveness and the costs must be evaluated 
simultaneously. That is, to have the most comprehensive understanding of the 
effects of allowing hospitals without backup surgical capabilities performing 
primary PCls the effects and costs must be evaluated simultaneously (5, 6). 
Myers et al.'s initial study failed to include costs in the analysis. Therefore, the 
current study investigates the costs associated with allowing hospitals without 
onsite Coronary Artery Bypass Graft surgery (CABG) capabilities to perform 
primary PCI in the State of Kentucky. As such, combing the current study with 
our earlier results allows us to calculate an incremental cost-effectiveness ratio to 
investigate the cost-effectiveness of this pilot program and established whether it 
is financially feasible to perform primary PCI at hospitals without backup surgical 
capabilities. 
Myocardial Infarction 
A heart attack or myocardial infarction (MI) occurs when blood supply to 
the heart is disrupted by an occlusion in one or more of the coronary arteries. 
This deprivation of blood to the heart muscle causes damage or possibly death to 
the heart's tissues known as myocardium (7). It is been well established that the 
longer the heart is deprived of blood, the more heart muscle is damaged and 
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killed. The axiom cardiologist have is that time saved is heart saved; thus, 
establishing the need to open the coronary arteries occluded as quickly as 
possible (2). 
Some of the symptoms of a heart attack are chest pain or angina, 
shortness of breath, profuse sweating, burning sensation in the esophagus, and 
radiating pain to the arms and legs, especially on the left side of the body. 
Individuals who have previously been diagnosed with cardiovascular disease are 
aware of these symptoms and know that they must manage the pain with 
nitroglycerin and aspirin (2, 8, 9). Since these symptoms are also common 
symptoms of less severe illnesses (e.g., heartburn) it is not recommended that 
an individual seek medical attention unless the pain does not subside within five 
minutes. Then the individual should visit an emergency department to alleviate 
their pain and receive treatment. 
Diagnosis of a MI 
Once a patient is at the emergency department, emergency personnel will 
follow a well established and studied algorithm to determine if the individual is 
experiencing a MI. Nonetheless, emergency departments routinely begin 
treatment for an MI, believing a false-positive (treating a MI while the patient truly 
has, for example, heart burn) is a less severe mistake to make than a false-
negative (treat for heart burn while the patient is experiencing aMI) (10). 
The patient (and/or their relatives) will be asked several questions 
concerning the patient's medical history to determine their risk of a heart attack. 
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In addition, a series of diagnostic tests will be conducted immediately upon 
arrival to the hospital: electrocardiogram, blood test, and echocardiogram. The 
electrocardiogram (ECG) and echocardiogram (ECHO) are usually performed in 
tandem. While an electrocardiogram assess the electrical activity of the heart, an 
echocardiogram uses ultrasound to produce images of the heart structures. The 
benefits of these tests will be discussed below, but the results of these tests 
allow cardiologists to determine the exact type of MI a patient is experiencing 
(e.g., STEMI). The most definitive test to establish if a MI is occurring is the 
confirmatory blood tests. The human body only produces changes in the levels of 
the enzymes troponin and creatine kinase if the heart muscle has recently been 
damaged. Therefore, if these enzymes show in the blood test, it is very definitive 
that a MI has occurred (10). 
STEMI 
One of the least predictable and most severe heart attacks is classified as 
ST-elevated myocardial infarction (STEMI). It is caused by sudden clots, known 
as thrombotic occlusions, in the coronary arteries which had not experienced any 
narrowing previously (11). They are indicated by the electrocardiogram (ECG) 
that is performed upon admission to the emergency department when the ECG 
displays an abnormal elevation in the "ST segment" of the electrical heart wave. 
STEMI is considered the most severe type of heart attack because it is caused 
by a complete occlusion of one of the coronary arteries. The less blood flows 
into the heart and the longer the diminished flow lasts, the greater the damage to 
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the heart muscle (myocardium) and the less likely the patient will recuperate. 
Treatment of STEMI 
Currently, there are three options to treat patients experiencing a STEMI 
heart attack: (1) thrombolysis, (2) percutaneous coronary intervention (PCI), also 
known as balloon angioplasty, and (3) coronary artery bypass graft surgery 
(CABG) if three or more occlusions have occurred (8, 9, 11). 
Thrombolysis consists of injecting the patient with clot-diluting drugs in 
order to open the blocked artery. However, thrombolysis has been considered a 
less effective and less efficacious reperfusion technique since it takes an 
extended amount of time to begin to work (3, 8). By the time thrombolysis dilutes 
the clot, too much of the myocardium is dead or damaged severely. 
Thrombolysis was the first strategy developed to combat occlusions. However, 
more recently, PCI has been repeatedly shown in numerous differing populations 
to be more effective and efficacious when compared with thrombolysis, in 
preserving more of a patient's myocardium. PCI has shown to have superior 
clinical outcomes such as lower mortality rates, lower rates of recurrence of 
thrombotic occlusion, lower rates of re-infarction, and shorter recovery times to a 
productive life (11-15). 
PCI Procedure 
PCI (emergency angioplasty) is performed in a series of steps with slight 
variations for an individual case. Once the patient presents at the emergency 
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facility, the patient is treated with a fibrinolytic agent unless contraindicated by 
the patient's clinical condition such as ventricular arrhythmias or cardiogenic 
shock (2, 3, 8, 16, 17). Subsequently and immediately an angiogram is 
performed. During an angiogram, a catheter is inserted into one of the femoral 
arteries (located in the groin/thigh) and guided to the coronary arteries. The 
femoral arteries are the largest arteries in the body. Injuries to the femoral artery 
used can result very rapidly in severe blood loss and possible death; thus, the 
need for PCI's to be performed by experienced surgeons, well-staffed and 
experienced catheter labs, and at well-equipped facilities. A contrasting 
substance is then injected into the vessel to make the area surrounding the heart 
clear in the X-ray images. It is this tool that allows the emergency personnel to 
determine what vessels are blocked. After the affected area has been 
determined, a balloon catheter is inserted and guided to the blocked vessel. 
Once in place, the balloon is inflated to open out the walls of the blood vessel 
and crush the clot. Also, it is recommended to place a tubular mesh, know as a 
stent, in the affected segment of the blood vessel to prevent the collapsing of the 
vessel's walls. Finally, the catheter is often removed and the entry-puncture 
sealed; or the catheter may be left in place up to twelve hours depending on the 
length of time needed to thin the patient's blood. After successful angioplasty, 
most patients are discharged within 24 hours of the procedure. 
One key aspect for PCI to be successful is the door-to-balloon time (DTB) 
(16, 18-22). This is the length of time between the patient arriving at the 
emergency facility and the moment the balloon is inflated in the affected segment 
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of a blood vessel. After many clinical studies, it has been determined that the 
DTB should be less than 90 minutes. The reason for this timeframe is that it 
provided, in multiple clinical trials, lower in-hospital death rates, reduced 30-day 
mortality rates, shorter average lengths of stay in the hospital, lower rates of 
reinfarction, and lower rates of reocclusion (18, 20, 22-24). 
Issue with Primary PCI at hospital without onsite CABG Capabilities 
An inherent risk to performing primary PCI is accessing or puncturing the 
femoral artery, which is a large artery, and may lead to a patient "bleeding out" 
very fast and leading to the patient's death if not corrected quickly. Also, issues 
may arise during the procedure such as an abrupt closure of the previously 
opened artery. In addition, patients with elevated risks for MI and other co-
morbidities may need to be transferred to an operating room that is capable and 
equipped to perform open-heart surgeries. Therefore, it is recommended that 
facilities performing PCI's should have appropriate onsite back-up surgical 
capabilities (3). 
The decision to allow hospitals without CABG capabilities to perform 
primary PCI rests on each state's regulatory body. While the American College 
of Cardiology/American Heart Association (ACC/AHA) guidelines give primary 
angioplasty without surgical backup a class 2b indication ("probably reasonable"), 
30 states currently allow hospitals without surgical open heart surgery (SOS) 
capabilities to perform primary (emergency) PCI. A myriad of studies, mostly 
retrospective, have shown that no difference in clinical outcomes exists between 
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hospitals with CABG capabilities and hospitals without surgical backup for 
primary PCI (4, 23, 25-31). 
Since, in the state of Kentucky, most cases of heart attack seem to 
originate in rural areas and the state of Kentucky did not permit the delivery of 
primary PCI in hospitals without surgical backup, a three-year pilot study to 
assess the soundness of allowing select facilities in Kentucky to perform primary 
PCI despite lacking onsite surgical backup was implemented in 2005 (4). It 
involved two regional hospitals without onsite CABG capabilities: T.J Samson 
Community Hospital in Glasgow, Ky and Ephraim McDowell Regional Medical 
Center in Danville, Ky. This study concluded that there was no significant 
difference in any of the clinical outcome between facilities with and without 
emergency backup capacity. Recommendations from this study included the 
revision of the ACC/AHA guidelines for primary PCI by allowing hospitals without 
backup open-heart surgical capabilities to perform emergency PCI with 
restrictions on surgeon's experience, catheterization lab team training, and 
facilities volume. 
Current Study 
By incorporating the costs associated with the pilot program in addition to 
the effectiveness of the program, a Cost Effectiveness Analysis (CEA) can be 
executed to evaluate the cost-effectiveness of allowing hospitals without onsite 
CABG capabilities to perform primary PCI. Therefore, the current study alludes 
to the financial feasibility of allowing these hospitals to do emergency PCI in 
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addition to hospitals with onsite open-heart surgery capabilities. 
Specifically, the current study focuses on the cost-effectiveness of 
allowing select facilities in Kentucky to perform primary PCI despite lacking 
onsite surgical backup capabilities, when compared to only allowing hospitals 
with back-up surgical capabilities to perform primary PC. In addition, the current 
study discusses further potential savings in costs due to such effects as shorter 
hospital length of stays, transfer costs, readmission costs, and possibly the 





Myocardial infarction (MI), also known as a heart attack, is the damage or 
possible death that the specialized heart's tissue known as the myocardium 
experiences when blood supply to the heart is blocked (10). MI can be classified 
in five types: 
• Type 1: spontaneous and related to ischemia due to a coronary event. 
• Type 2: secondary to ischemia due to an imbalance between oxygen 
demand and supply. 
• Type 3: sudden cardiac death with symptoms of ischemia and new 8T 
elevation or LBBD, verified thrombus by angiography, or autopsy. 
• Type 4a: associated with previously performed PCI. 
• Type 4b: associated with verified stent thrombosis. 
• Type 5: associated with CABG. 
However, for practical purposes, and in clinical settings, a MI is classified 
from based on results from an electrocardiographic diagnostic test that assesses 
the heart's various electrical waves to determine the precise site of the infarction 
(7,9): 
• Inferior (or diaphragmatic) wall: II, II and aVF 
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• Septal: V1 and V2 
• Anteroseptal: V1, V2, Vf3 and sometimes V4 
• Anterior: V3, V4 and sometimes V2 
• Apical: V3, V4 or both 
• Lateral: I, aVL, V5 and V6 
• Extensive anterior: I, aVL and V1 through V6 
According to the ECG reading the severity of the MI can also be determined 
as either STEMI, the most severe, or NSTEMI (2). STEMI will display an 
elevation in the ST segment of the T-wave, which represents a total occlusion of 
a coronary artery. 
Development of Thrombolytic Therapy 
Thrombolytic or fibrinolytic therapy was originally studied and developed in 
the 1950's with promising results by Dr. Sol Sherry who demonstrated that 
streptokinase could dissolve blood clots that typically occluded coronary arteries. 
However, more recent reperfusion theory demonstrates that thrombosis is a 
secondary event in ischemic events. Long after the advance that a coronary 
occlusion was an etiology of acute myocardial infarction, the Gruppo Italiano per 
10 Studio della Streptochinasi nell'lnfarcto miocardio (GISSI) study (in 1986) 
established through a multicenter randomized clinical trial that in-hospital 
mortality was reduced by more than 3% following streptokinase administration 
(8). Yet, streptokinase and other first generation thrombolytic agents came with 
the limitation of being immunogenic and with a third of the patients receiving 
therapy being unresponsive to such therapy. DNA research advances led to 
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fibrin specific plasminogen activators, which resulted in much lower rates of 
mortality and risk reduction when compared to streptokinase to treat AMI leading 
to extended hope for thrombolysis. Similarly, aspirin demonstrated similar 
survival benefits to those of streptokinase alone in several clinical trials. 
Development of Percutaneous Coronary Intervention 
PCI, or angioplasty, was developed in 1977 when the Swiss radiologist 
Andreas Gruentzig performed the first percutaneous transluminal coronary 
angioplasty on a thirty-eight year old patient with a left coronary artery lesion 
(17). Compared to today's equipment, the catheters were large and could easily 
injure a blood vessel. In addition, no guidewires were used and balloon 
catheters would discharge suddenly at low pressure levels. This rendered this 
type of intervention available to only ten percent of patients needing 
revascularization. Fortunately, during the early 1908s, the catheters were 
manufactured smaller and balloons were designed to inflate at higher pressures, 
which made balloon angioplasty available to nearly 50% of patients in need of 
revascularization. However, one of the drawbacks of balloon angioplasty is that 
it fractures plaque that is causing the current occlusion. The fissured atheroma 
may cause the formation of a new thrombus later. Another limitation is the 
weakening of the vessel which may cause the vessel to recoil resulting in 
restenosis. As a result, new devices aimed to combat these limitations were 
developed and manufactured. The transluminal extraction catheter and excimer 
laser enabled the development of atherectomy, although they were not 
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associated with a reduction in the incidence of restenosis rendering these 
instruments as niche tools. It wasn't until the advent of coronary stents in 1986 
that PCI was shown to be safe and more effective by significantly reducing 
restenosis. Improvements to stents such as pharmacologic coating and various 
levels of flexibility and strength followed in the 1990s and the first decade of the 
twenty-first century. 
Effectiveness of PCI 
Several clinical trials have been conducted to investigate the effectiveness 
of PCI compared to adjunctive therapy in NSTEMI patients. A key idea in these 
results was the stratification of the patients according to the Thrombolysis 
Myocardial Infarction (TIMI) score, which classifies patients as high, medium, or 
low risk. High-risk patients, with TIMI scores of five or greater, are those with 
three or more of the following characteristics: prolonged chest pain, hypotension, 
65-years of age or older, ST -segment changes, and elevated biomarkers levels 
(32). Retrospective stUdies based on the Global Registry of Acute Coronary 
Events (GRACE) and the Euro Heart Survey of Acute Coronary Syndromes 
found that the proportion of patients with an admission diagnosis of unstable 
angina or MI quickly progress to NSTEMI (24% and 21 % respectively) or to 
STEMI (6% and 69% respectively) (16, 33). These two studies also found that 
hospitals with a catheterization lab treat 53% (in the US) and 25.4% (in Europe) 
of patients with a diagnosis of NSTEMI with PCI. Researchers from the clinical 
trial TIMIIIIB (34), found three significant independent predictors of late positive 
troponin, a confirmatory biomarker for MI, (1) levels for patients presenting with 
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ACS and early negative troponin levels: TIMI 3 (OR=3.52, 95% CI = 2.38-5.23, 
p<0.001), (2) ST-deviations (OR=2.91 , 95% CI =1.92-4.40, p<.001), and (3) no 
prior use of beta blockers (OR=1.74, 95% CI=1.15-2.63, p=.008). For patients 
with a high-risk score, most studies have found that an early aggressive 
reperfusion therapy, PCI or CABG, resulted in better clinical outcomes when 
compared to a conservative therapy of pharmacologic agents (table 1). In FRISC 
II, a clinical trial comparing early invasive with non-early invasive strategies at 
one year follow-up found that the composite outcome of death or MI occurred in 
10.4% of those in the early invasive arm and 14.1 % of those in the non-early 
invasive arm with a p-value of 0.015 (35). A new meta-analysis by Dr. Keith Fox 
found that an aggressive approach leads to better long-term outcomes when 
compared to a more selective conservative strategy (table 2) (36). The decision 
between PCI and CABG is primarily based on anatomical and physiological 
characteristic of the injury. For example: left main coronary artery disease, 
compromised left ventricular function, diabetes, and/or three or more vessel 
injuries are treated with CABG, while two or fewer vessel injuries are reperfused 
with PCI (32). 
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Table 2. Cox regression of outcomes stratified by selective and routine invasive procedures. 
Outcomes Selective Invasive Routine Invasive Hazard Ratio p-value 
MI 10.0% 0.77 .001 
CV death 8.1% 6.8% 0.83 .068 
CV death/MI 17.9% 14.7% 0.81 .002 
All-cause mortality 11.7% 10.6% 0.90 .190 
All-cause mortality/MI 20.9% 18.1% 0.85 
Similarly, a myriad of clinical studies and retrospective studies based on 
registries have been conducted to investigate the difference in clinical outcomes 
between primary PCI and thrombolytic therapy. A vast majority of the studies 
have concluded that PCI resulted in better long-lasting outcomes when 
compared with fibrinolytic therapy (table 3). In a small trial by Zijlstra, tests for 
differences in unconventional outcomes that relate to an individual's long-term 
functioning were performed showing those managed with PCI had less unstable 
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angina (5.7% vs. 19.4% p=0.02), more left ventricular ejection (51 vs. 45 
p=0.004) and more patency in the related artery (91 vs. 68 p=0.001) (15). 
Likewise, GUSTO lib analysis concluded that PCI was superior to thrombolytic 
therapy. In 30-day follow-ups, a composite outcome of death, non-fatal 
reinfarction, and disabling stroke was measured in patients randomized to PCI 
and thrombolysis showing PCI's superiority in this composite outcome (9.1 % vs. 
13.7%, p=0.013). DANAMI-2 clinical trial also showed that PCI was superior to 
fibrinolytic therapy when it was stopped in the second interim study with a p-
value less than 0.009 in favor of PCI (40). Furthermore, the advent of stents and 
drug-eluting stents has resulted in superior outcomes in the latest trials and PCI-
registry analyses (32). In a meta-analysis comparing randomized clinical trials of 
primary PCI versus Thrombolysis, researchers found that the odds ratio of 
mortality at six weeks was 0.56 (0.33, 0.94) demonstrating that PCI was 
favorable (41). A key aspect of these studies is the time to reperfusion 
subsequent to hospital admission. The optimal time to reperfuse via PCI 
technique has been determined to be 90 minutes or less (3). For instance, a 
cohort study based on the American College of Cardiology National Data 
Registry indicated that longer door-to-balloon times were associated with higher 
risk of mortality in hospitals (24). The risk of in-hospital mortality increased from 
3.0% with a 30-minute door-to-balloon time to 8.4% with a door-to-balloon time of 
180 minutes in non-linear fashion and with a p-value less than 0.001. 
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Table 3 
In-hospital 6 - Months / 1 - Year 
Authors Outcomes 
PCI Thrombolysis PCI Thrombolysis p-value 
value 
Grines et Death 2.6% 6.5% 0.06 NA NA NA 
al.21 Reinfarction 5.1% 12.0% 0.02 8.5% 16.8% 0.02 
Zijlstra et Death 0.0% 6.0% 0.13 NA NA NA 
al. 15 12.5% 0.003 NA NA NA 
Ribichini Death 1.8% 5.5% 0.6 3.6% 7.3% 0.7 
et al. 14 Reinfarction 9.1% 45.5% 0.0001 
Le May et Death 4.8% 3.3% 1.0 4.8% 3.3% 1.0 
al.42 Reinfarction 11.3% 42.6% 0.001 14.5% 49.2% 0.001 
Schoming Death NA NA NA 8.5% 23.2% 
et al.43 Reinfarction NA NA NA 10% 34.9% 
PCI at hospitals without onsite surgical backup 
Many of the retrospective studies based on registries have found that many 
cases of MI originate in rural areas where most hospitals lack open-heart surgery 
capabilities (23, 28, 30). Between 1998 and 2002, Alamance Regional Medical 
Center offered primary PCI under the guidance of Duke University Medical 
Center as part of a pilot program (28). The inclusion criteria were those of low to 
moderate-risk patients according to the literature. A total of 561 interventions 
were performed with a success rate of 98%, adverse events included: one death 
due to acute renal failure after successful PCI, while the other 2% of the patients 
were transferred to Duke Medical Center where 0.7% had to undergo bypass 
surgery (successfully). Magic Valley Regional Medical Center (MVRMC) in Twin 
Falls, 10, implemented a program of providing PCI for acute coronary syndromes 
in a rural setting without surgical backup starting in 2003 (25). It compared its 
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outcomes with those of the ACC registry of 2004, which are considered the 
standard of care. The distributions of door-to-balloon times were statistically 
significant with that of MVRMC being lower than that of the ACC registry. The in-
hospital death rates were 1.96% for MVRMC and 1.16% for the ACC registry 
(p=0.1446) indicated not significant difference. Only one patient had to be 
transferred for open-heart surgery after the perforation of the left anterior artery. 
The transport time to Boise was 100 minutes, and the surgery did not have any 
complications. 
In 2000, the New York State Department of Health, which has a Certificate of 
Need system for limiting the number of hospitals in which CABG surgery and PCI 
can be performed, began to allow a limited number of hospitals to perform 
emergency (primary) PCI for patients with STEMI. By 2006, a total of 11 
hospitals were certified to perform PCI without surgical backup (henceforth called 
P-PCI centers). This study compares patient outcomes for patients with STEMI in 
those hospitals with patient outcomes in full service (FS) cardiac hospitals 
(hospitals that perform CABG surgery as well as P-PCI and elective PCI)" (table 
4) (26). The PAM I-No SOS study showed that primary PCI in high-risk STEMI 
patients in hospitals without on-site cardiac surgery is safe, effective and faster 
than primary PCI after transfer to a surgical facility (31). Locally, the state of 
Kentucky conducted a pilot study to investigate the soundness of allowing select 
facilities in the state to perform primary PCI despite being devoid of onsite 
emergency backup capabilities (4). It concluded that clinical outcomes were not 
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different between the local hospitals and the national standard and that study 
populations were similar to those of national PCI registries. 
Table 4 
In-hospital/30-day mortality 






Cost Benefit of PCI vs. Thrombolysis 







As early as 1994, the Mayo Clinic conducted a study to compare costs of 
immediate PCI and thrombolytic therapy for acute coronary syndromes (44). The 
Mayo Clinic's hypothesis was that thrombolysis followed by adjunctive medical 
treatment was more cost-effective than angioplasty. However, the researchers 
arrived at the conclusion that there was no difference in cost-effectiveness within 
a twelve-month period. In 1993, the Health Technology Assessment Programme 
in the UK embarked in a long-term cost-effectiveness analysis of primary 
angioplasty taking the perspective of the UK's National Health System (NHS) 
with the subsequent results being published in 2005 (45). Their results 
consistently and convincingly demonstrated a clinical advantage of immediate 
PCI over thrombolysis. No evidence was found suggesting that services should 
be concentrated in to large hospitals in metropolitan areas despite evidence that 
larger volumes of the procedure resulted in lower levels of mortality. The 
economic evaluators compared PCI with thrombolytic therapy for people with 
AMI; they found that PCI was more cost-effective than thrombolysis even when 
taking into account variations in the cost of drugs and health status of the 
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patients. Khot et aI., conducted a small prospective analysis of the costs related 
to reducing the door-to-balloon time for STEMI patients at St. Francis Hospital 
and Health Center (Beech Grove and Indianapolis, IN) (46). They concluded that 
all of the financial benefits of reducing DTB in STEMI patients are obtained by 
the payers both during initial hospitalization and after one-year follow-up. 
Gap in the Knowledge Base 
As detailed above, it is well established that PCI should be the advocated 
management strategy for AMI patients, especially those experiencing a STEMI. It 
is also well established that PCI is cost-effective when compared to thrombolysis 
and that it is medically sound to allow hospitals without backup surgical 
capabilities to perform primary PCI. The gap in the knowledge base is whether it 
is cost-effective to allow hospitals without surgical backup capabilities to perform 
PCI, when compared to only allowing hospitals with backup capabilities to 
perform PCI. Therefore, the results of this thesis will push forward the knowledge 




ST-elevation myocardial infarction (MI) is considered one the leading 
causes of acute cardiac syndromes. During the last decade, many technological 
and methodological developments have occurred in interventional cardiology that 
is aimed to assist with this type of MI. Such progress has made percutaneous 
coronary interventions (PCl's) safe and effective in the treatment of acute MI 
(AMI), in particular STEMI. During this time, many studies have shown that PCI 
produces significantly better outcomes than thrombolysis. Furthermore, these 
studies suggest that an aggressive treatment of STEMI is the more effective way 
to prevent deaths attributed to Ml's. As a result, the national guidelines 
developed by the American Heart Association and the American College of 
Cardiology advocates primary PCI as the preferred treatment for patients with 
STEMI. However, a key aspect for the success of PCI is the door-to-balloon 
time. Studies have consistently demonstrated a negative association with the 
outcomes from a PCI and DTB time: the longer the DTB time, the less likely PCI 
will be successful. During the last decade many interventional cardiologists and 
public health administrators have promoted the idea of allowing regional 
hospitals without open-heart surgery-on-site capabilities to perform primary PCI 
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as one way to address this issue in rural areas. It was the objective of this study 
to determine the cost-effectiveness of allowing selective regional hospitals 
without surgical backup for coronary artery bypass to perform primary PCI. The 
medical soundness of allowing selective regional hospitals without surgical 
backup for coronary artery bypass to perform primary PCI was established in our 
initial report from this pilot program. 
"Cost-effectiveness analysis is a method designed to assess the 
comparative impacts of expenditures on different health interventions ... based on 
the premise that 'for any given level of resources available, society wishes to 
maximize the total aggregate health benefits conferred.' The central measure 
used in cost-effectiveness analysis is the cost-effectiveness ratio. Implicit in the 
cost-effectiveness ratio is a comparison between alternatives. The cost-
effectiveness ratio for comparing the two alternatives is the difference in their 
costs divided by the difference in their effectiveness, or CIE." 
The measurement of effectiveness for the current study is the number of 
deaths averted. The effectiveness estimates have been derived from a 
systematic literature review of national prospective studies based on PCI 
registries as well as our earlier study evaluating the KENTUCKY PILOT 
PROJECT FOR PRIMARY PCI WITHOUT ONSITE CABG (4). Such studies 
have shown that differences in effectiveness of PCI between the two alternatives 
(allowing/not allowing these regional hospitals to perform primary PCI) were not 
statistically significant). Five studies, from the literature review, were considered 
to have relevance and deemed pertinent for the current study. They were 
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selected by the author based on the study population, sample size, study design, 
outcome variables of interest, and follow-up time. Specifically of interest were 
studies that included mortality rates stratified by door to balloon time intervals, 
complication rates due to the differing physiology of the patients and due to 
catheterization, and the corresponding emergency surgery rates. The measures 
of clinical complications comprised several major adverse coronary cardiac 
events: stroke, bleeding, infarction size, and repeated PCI. Table 1 provides a 
description on where these selected studies were conducted, type of study 
design employed, and outcome measures evaluated. Clearly, most studies 
favored a short door to balloon time. Also, many of the studies suggested that it 
is efficacious to allow regional hospitals without surgical backup to perform 
primary PCI. For example, the study "Safety In Numbers For Community 
Hospitals Performing Emergency Angioplasty" from Johns Hopkins University 
School of Medicine and its Heart and Vascular Institute found that the mortality 
rate in nonsurgical hospitals to be 2.2% and not significantly different from the 
mortality rate observed in hospitals equipped with open-heart surgical facilities. 
Also from this study, the proportion estimates for a door-to-balloon time less than 
or equal to 90 minutes was determined to be 44.8%. Similarly, our earlier report 
evaluating the KENTUCKY PILOT PROJECT FOR PRIMARY PCI WITHOUT 
ONSITE CABG found that there were no differences in mortality rates, 
emergency surgery as a result from PCI, and door-to-balloon time between 
regional non-surgical hospitals and national estimates from hospitals with open 
heart surgery capabilities. 
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Table 5. Studies used in the economic analysis. 
Study Local Type of study Outcomes 
Darwazah et al. Makassed Hospital, Israel Audit Mortality, OHS 
K. Haan at al. Univ. of Florida, USA Audit Mortality, OHS 
Mattichak William Beaumont Hospital, USA Audit PCI complications 
McNamara et al. Yale Univ., USA Cohort Mortality, OBT 
Moscucci et al. Univ. of Michigan, USA Audit Mortality, OHS 
Mishra et al. Queen Elizabeth Hospital, Australia Audit Mortality, OHS 
Univ. of Louisville, USA Pilot, Cohort Mortality,OHS, OBT 
Ong et al. Changi General Hospital, Singapore Review Mortality, OHS 
Rathore et al. Yale Univ., USA Cohort Mortality, OBT 
Seshadri et al. Cleveland Clinic, USA Audit Mortality, OHS 
Yang et al. Mayo College of Medicine, USA Audit Mortality,OBT 
Intervention Costs 
The National Inpatient Sample (NIS) database contains all-payer data on 
hospital inpatient stays from states participating in the Healthcare Cost and 
Utilization Project (HCUP). The database consists of three tables with records 
from the year 2005: inpatient records, hospital characteristics, and severity index. 
One of the NIS main functions is to promote comparative studies on costs and 
the use of hospital services. The NIS contains information on nearly eight million 
hospital stays for the year 2005, which makes the NIS the largest database of all-
payer inpatient observations. The inpatient records table contains one record per 
inpatient admission with information about primary and secondary diagnosis, 
primary and secondary procedures, patients' demographics, admission and 
discharge status, total charges, and length of stay. The charge information is 
collected on all patients regardless of payer; that is, it includes coverage 
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information from patients covered by Medicare, Medicaid, private insurance, as 
well as those who are uninsured. The hospital characteristics table has 
information on 1,056 hospitals that comprise the sample. This table contains 
information such as hospital ownership, size, teaching status, region, 
metropolitan area, and hospital 10 that corresponds to records in American 
Hospital Association database. The design of the sample is to approximate a 
twenty percent sample of the U.S. community hospitals, which encompasses 
specialty hospitals, public hospitals, and academic medical centers. The hospital 
universe is defined by all hospitals that were open during any part of each 
calendar year and were designated as community hospitals in the American 
Hospital Association Annual Survey Database. 
In determining costs, the inpatient table was first filtered to contain only 
observations corresponding to a principal diagnosis of STEM!. This was 
achieved by filtering by using the ICD-9 code 410. Hospital information was 
added by linking this table to the hospital characteristic table using the hospital 
10. Subsequently only observations from the Midwest and South were retained 
to make cost more appropriate for the regional hospitals evaluated. From this 
subset, observations corresponding to primary PCI were identified using the 
procedures variables: the corresponding ICD-9 code used was 00.66, and all 
non-PC I records were dropped. Then, observations corresponding to emergency 
CABG were identified by using the ICD9 code 36.1X. Finally, cost estimates 
were obtained for primary PCI only for facilities without onsite backup and for 
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facilities with surgery on site capabilities. Table 2 summarizes the codes used to 
obtain these costs. 





















Acute Myocardial Infarction 
Percutaneous transluminal coronary angioplasty 
Procedure on single vessel 
Procedure on two vessels 
Procedure on three vessels 
Procedure on four or more vessels 
(Aorto) coronary bypass of one coronary artery 
(Aorto) coronary bypass of two coronary arteries 
Aorto) coronary bypass of three coronary arteries 
(Aorto) coronary bypass of four or more coronary arteries 
Insertion of non-drug-eluting coronary artery stent(s) 
Insertion of one vascular stents 
Insertion of two vascular stents 
Insertion of three vascular stents 
Insertion of four or more vascular stents 
The current study was focused on Kentucky's policy on primary PCI. The 
question of interest is "Is allowing hospitals without open heart surgical backup to 
perform primary PCI cost effective?" The evaluation developed for this 
assessment is based on a 3D-day decision-analytical model, which examines the 
benefits and costs of two strategies: (1) performing primary PCI only in hospitals 
with backup surgery and (2) performing primary PCI in both hospitals with and 
without CABG capabilities (that meet the recommendations in Myers et al.). The 
model displays the likelihood a patient having an acute myocardial infarction 
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experiences all plausible and relevant c events (See figure 1 and table 3). The 
structure of the model, presented in figure 1, was developed using evidence from 
a systematic literature review of clinical effectiveness of primary PCI. The model 
represents the pivotal states that would determine both the costs and 
effectiveness of the alternative treatment options for people experiencing an 
acute myocardial infarction. The economic evaluation focused on estimating the 
incremental cost effectiveness ratio (ICER) of allowing the regional hospitals to 
perform primary PCI. The perspective of the study is from the payer. As a 
consequence, capital costs, training costs, and overhead costs were not included 
in this study. Uncertainty about the model parameters was investigated through 
employing sensitivity analysis techniques, which tested how the assumptions 
affected the outcomes and sensitivity of each variable. As a result, the model for 
this study includes two main pathways in the analysis tree for treatment of acute 
myocardial infarction (AMI). It shows that patients suffering from an acute 
myocardial infarction have two options: (1) only be allowed to receive a primary 
PCI in a hospital with open-heart surgery backup or (2) also (for those in rural 
areas) being allowed to receive a primary PCI in a hospital without CABG 
capabilities. When an individual experiences an AMI, they will usually be 
transported to nearest hospital. This primary center may be equipped with 
surgical-on-site capabilities or, if in a rural area, may be a hospital without 
surgical backup. A key aspect in the treatment of AMI, in particular of STEMI, is 
the response time of the medical facility. In particular, the door-to-balloon time 
(DBT) is critical in the effectiveness of primary PCI, in particular with respect to 
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mortality and morbidity. OBT refers to the time from the moment the individual 
arrives to the hospital to the moment when the catheter crosses the culprit lesion 
and a balloon is inflated to open up the artery's blockage. Based on many 
studies, the American Heart Association and the American College of Cardiology 
have established as a guideline that OBT is not to exceed 90 minutes. This 
means that the proportion of patients with a door-to-balloon time greater than 
ninety minutes is associated with a higher rate of mortality and unsuccessful PCI. 
Clearly, requiring that a person suffering from an AMI be transported to a facility 
with surgical backup capabilities increases and is associated with increases in 
OBT. Thus, allowing individuals in more remote areas to receive a PCI at a 
regional facility may be beneficial. 
It is well established that medical interventions, even those successfully 
performed, do not guarantee a successful outcome. Primary PCI can have two 
direct outcomes regardless of door to balloon time: mortality and intervention 
survival. Having survived primary PCI occurs in two health states: successful 
PCI and complications. Patients who survive the intervention may have 
complications requiring emergency open-heart surgery or minor complications 
related to their physiology. Those patients who do not require emergency 
surgery are considered as lives saved with utility value of 1. Alternatively, the 
complications lead to emergency coronary by-pass surgery with resulting 
outcomes of mortality or success as a saved life. 
The cost-effectiveness ratios are computed by taking the difference in 
costs from the two clinical facilities for primary PCI while the denominator is 
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obtained by the difference in number of deaths prevented on each branch. 
Sensitivity analysis was conducted for the estimated proportions of door to 
balloon time and complications with respect to the hospital categories. In 
addition, estimated costs for primary PCI and emergency coronary bypass 
surgery are analyzed up to a two-fold increase for both branches. 
29 










































pLESSa _____ _ 
pLESFa 
Definitions 
S art Door to Balloon Time for surgical hos(:!itals «=90 min) 
Long Door to Balloon Time for surgical hospitals (>90 min) 
Short Door to Balloon Tim for all hospitals «=90 min) 
Long Door to Balloon Time for all hospitals (>90 min) 
Mortality and Short Door to Balloon Time for surgical hospitals 
Mortality and Long Door to Balloon Time for surgical hospitals 
Mortality and Short Door to Balloon ime for all hospitals 
Mortality and Long Door to Balloon Time for all hospitals 
Complications after PCI for surgical hospitals 
Complications after PCI for all hospitals 
Failed PCI given SDBT for surgical hospitals 
Successful PCI given SDBT for surgical hospitals 
PCI complications given SDBT for surgical hospitals 
PCI mortality given SDBT for surgical hospitals 
_-...---------. 
a'ied PCI g'ven LDBT for surgical hospitals 
Successful PCI given LDBT for surgical hospitals 
-:------. PCI complications given LDBT for surgical hospitals 
PCI mortality given LDBT for surgical hospitals 
Failed PCI given SDBT for all hospitals 
Successful PCI given SDBT for all hospitals 
PCI com(:!lications given SDBT for all hospitals 
PCI mortality given SDBT for all hosptitals 
Failed PCI given LDBT or all hospitals 
Successful PCI given LDBT for all hospitals 
--~--~~-------, PCI complications given LDBT for all hosRitals 
PCI mortality given LDBT for all hospitals 
Emergency Surgery given SDBT for surgical hospitals 
Not Emergency Surgery given SDBT for surgical hospitals 
Emergency Surgery given LDBT for surgical hospitals 
Not Emergency Surgery given LDBT for surgical hospitals 
Emergency Surgery given SDBT for all hospitals 
Not Emergency Surgery given SDBT for all hospitals 
Emergency Surgery given LDBT for all hosRitals 
Not Emergency Surgery given LDBT for all hospitals 
Emergency Sur ery Success give SDBT 0 surgical ospitals 
Emergency Surgery Failure given SDBT for surgical hospitals 
~--Emergency Surgery Success given LDBT for surgical hospitals 
Emergency Surgery Failure given LDBT for surgical hospitals 
Emergency Sur ery Success given SDBT for all hos itals __ .... 
Emergency Surgery Failure given SDBT for all hospitals 
'7:'":"-~-:------"" ergency Su gery Success given LDBT for all hosRitals 
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This study was designed to extend previous findings from our earlier 
report, the Kentucky Pilot Project for Primary PCI without On site CABG; which 
demonstrated that there were no statistical differences in outcomes between 
facilities with onsite emergency backup capabilities and those that lacked such 
capabilities when compared to established values. With the exception that 
T JSCH had a higher proportion of individuals who received their CABG in less 
than 90 minutes. Tables 3 and 4 show the results from the original study, which 
suggests the there is no significant difference in any of the outcome variables 
studied between facilities with and without onsite emergency open heart surgery 
capabilities. 
Since costs estimates were obtained from the 2005 National Inpatient 
Sample (NIS), the NIS data set was statistically investigated for many of the 
variables that were evaluated in the Kentucky Pilot Project for Primary PCI 
without On site CABG report. To allow for a more direction comparison with the 
earlier report, the NIS was initially filtered to include only observations in the 
Midwest and Southeast. This resulted in a sample of 7,586 subjects who 
received an emergency PCI. A majority of the cases were obtained from facilities 
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with emergency backup capabilities (n=7,248); while only 338 of the observations 
came from individuals seen at facilities without open-heart surgery capabilities. 
Table 3 shows the main demographic characteristics stratified by facility type. In 
the NIS population the mortality rate was 2.8% for individuals seen at hospitals 
with onsite CABG capabilities, while the mortality rate was 3.5% for individuals 
seen at hospitals, which did not have onsite CABG capabilities. 
Table 8. Comparisons of T JSCH Outcome Measures and the national values. 
Outcome TJSCH Reference p-value (n = 158) Values 
Mortality 
- In-hospital, n (%, 95% CI) 
- WI onsite CABG 4 (2.5, 0.7-6.4) 2.2% 0.9186 (NS) 
- W/O onsite CABG 2.2% 0.9186 (NS) 
Door-to-Bailoon Time 
- WI onsite CABG 92.7 mins 100.4 mins 0.0728 (NS) 
- W 10 onsite CABG 94.0 mins 0.7630 (NS) 
Door-to-Bailoon Time < 90 minutes 
- n/Total (%) 
- WI onsite CABG 90/158 (57.0) 44.8% 0.0028 (*) 
- W/O onsite CABG 44.8% 0.0028 (*) 
Cardiac Arrests 
- PCI Related , n (%, 95% CI) 
- WI onsite CABG o (0.0, 0.0-2.3) 0.4% 1.0000 (NS) 
- WIO onsite CABG N/A N/A 
Emergency OH Surgeries Performed, 
- PCI Related, n (%, 95% GI) 
- WI onsite GABG o (0.0, 0.0-2.3) 0.4% 1.0000 (NS) 
- W/O onsite GABG 0.3% 1.0000 (NS) 
About thirty-three percent of the patients were female in the hospitals with 
open-heart surgery capabilities, while in the hospitals without open-heart 
capabilities the proportion of female patients was about thirty-seven percent. 
The mean age for PCI patients in emergency-surgery capable hospitals was 
62.48 years, compared to a mean age of 63.08 patients in non-emergency-
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surgery capable hospitals. The proportion of patients needing emergent CABG 
after unsuccessful PCI was 2.47% in open-heart-surgery capable facilities while it 
was only 0.8% in facilities without open-heart-surgery capabilities. In addition, 
the mean length of stay was very similar for facilities with and without CABG 
capabilities: 4.36 days and 4.41 days respectively. None of these characteristics 
were statistically significantly different between individuals seen at these two 
types of facilities. 
Table 9. Comparisons of EMRMC Outcome Measures and the national values. 
Outcome EMRMC Reference p-value (n = 77) Values 
Mortality 
- In-hospital, n (%, 95% CI) 
- WI onsite CABG 2.2% 1.0000 (NS) 
- W/O onsite CABG 2.2% 1.0000 (NS) 
Door-to-Balloon Time 
- WI onsite CABG 100.1 mins 100.4 mins 0.9524 (NS) 
- WIO onsite CABG 94.0 mins 0.2167 (NS) 
Door-to-Balloon Time < 90 minutes 
- n!Total (%) 
- WI onsite CABG 28/56 (50.0) 44.8% 
- W/O on ite CABG 44.8% 
Cardiac Arrests 
- PCI Related, n (%, 95% CI) 
- WI onsite CABG 0(0.0,0.0-4.7) 0.4% 1.0000 (NS) 
- W 10 onsite CABG N/A N/A 
Emergency OH Surgeries Performed, 
- PCI Related, n (%, 95% CI) 
- WI onsite CABG 0(0.0,0.0-4.7) 0.4% 1.0000 (NS) 
- WIO onsite CABG 0.3% 1.0000 (NS) 
To provide a more comprehensive evaluation of the NIS data set, patients 
not requiring emergency CABG following emergent PCI were compared between 
the two types of facilities (Table 3). For hospital with open-heart-surgery 
capabilities, the mortality rate was 2.69%, the proportion of female patients was 
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33.56%, the mean age was 62.42 years, the mean length of stay was 4.1 days, 
and the mean total charges was $54,675. For hospitals without open-heart-
surgery capabilities, the mortality rate was 3.58%, the proportion of female 
patients was 37.31 %, the mean age was 63.11 years , the mean length of stay 
was 4.23 days, and the mean total charges was $48,234. The only 
characteristic, which was significantly different between these two groups, was 
total charges. 
Table 10. NIS Outcome Measures by Primary Hospital Open Heart Surgery Capabilities 
Outcome WI onsite CABG WIO onsite CABG p - value 
Mortality 2.8% (2.4 - 3.2) 3.5% (1.6 - 5.5) 0.4370 
Female 33.34% (32.3 - 34.4) 36.96% (31.8 - 42.1) 0.1653 
Age 62.48 ± 13.22 63.08 ± 13.46 0.3600 
Emergency CABG 2.47% (2.1 - 2.8) 0.8% (0 - 1.9) 0.0632 
Length of Stay 4.36 ±4.12 4.41 ± 4.15 0.8400 
Similarly, patients requiring emergency CABG following emergent PCI 
were compared between the two types of facilities (Table 4). For hospital with 
onsite CABG capabilities, the mortality rate was 8.38%, the proportion of female 
patients was25%, the mean age was 62.73 years, the mean length of stay was 
11 days, and the mean total charges was $134,498. For hospitals without onsite 
CABG capabilities, the proportion of mortality was 0%, the proportion of female 
patients was 0%, the mean age was 64.66 years, the mean length of stay was 10 
days, and the mean total charges was $107,915. The mortality rate and the 
proportion of females were significantly different between hospitals with and 
without onsite CABG capabilities . 
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Table 11. Patients who did not have emergency CABG 
Outcome WI onsite CABG WIO onsite CABG 
Mortality 2.69°/~ 2.3 - 3.1) 3.58 (1.6 - 5.6) 
Female 33.56% (32.4 - 34.6) 37.31 (32.1 - 42.5) 
Age 6 .27 63.11 ± 13.57 
Length of Stay 4.10 ± 3.39 4.23 ± 3.07 
Total Charges $ 54,675 ± 29,987 $ 48,234 ± 26.359 
# Stents 
----, 









Table 12. Patients who had emergency CABG 
Outcome WI onsite CABG 
Mortality 8.38% (4.3 -12.4) 
Female 25%(18.1-31.5) 
62.73 ± 11.82 
Length of Stay 11 ± 6.3 















10 ± 3.22 









< 0.0001 * 




Furthermore, kernel density estimation was used to estimate the 
probability density curve for age, length of stay and total charges. For patients 
who did not require emergent CABG following PCI, the probability density 
function for age tends to be uniform between the ages of 45 and 85 years old for 
both types of facilities. For patients requiring emergent CABG after PCI , the pdf 
for facilities without onsite CABG capabilities is lightly skewed to the left with a 
peak about 69 years while the cure for facilities with onsite CABG capabilities 
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has less kurtosis and is less skewed . These results would support normality and 
allow us to use parametric methods. 
Figure 1 
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The estimated curve for length of stay is skewed to the right, which was 
expected as this type of data tends to follow a lognormal or a gamma distribution. 
For patients who did not have emergency open heart surgery, the curve peaks at 
about 3 days. However, the curve corresponding to facilities without onsite CABG 
capabilities has less kurtosis than that correspond to facilities with onsite CABG 
capabilities. As expected from the resulting statistics, the curves for those 
patients who had emergent CABG peak much more to the right. For hospitals 
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with onsite open heart-surgery capabilities , the curve peaks near nine days and 
is severely skewed to the right. On the other hand, the curve for hospitals 
without onsite CABG peaks near twelve days and is slightly skewed to the left. 
Figure 3 
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Cost Estimates 
The main parameter obtained from the NIS data set for the current 
analysis is total charges for t.he two approaches, PCI and PCI+CABG. The 
estimated curves for those patients receiving only emergent PCI are both lightly 
skewed to the right, with the curve for facilities without onsite CABG capabilities 
peaking near $33,000 and kurtosis of 1.6; while the curve for facilities with onsite 
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CABG capabilities peaking further to the right at about $42,000 and kurtosis of 3. 
For patients having both emergent PCI and emergent CABG, the curve for total 
charges in facilities without onsite CABG capabilities was heavily concentrated 
near $93,000 while the curve for hospitals with onsite CABG is more evenly 
dispersed with peak at about $98,000. 
Figure 5 
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Probability Estimates 
Probabilities were estimated from studies that evaluated the relevant 
outcomes of interest. In addition the sample size and study design of the reports 
were evaluated as well to evaluate their usefulness. To provide precise 
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estimates of these probabilities, traditional meta-analysis techniques were used. 
That is, the sample sizes for each study were aggregated (N), the numbers of 
cases were aggregated (n), and then the ratio was computed (n/N). Table 5 
displays the estimated probabilities for the outcomes of interest for hospitals with 
onsite CABG capabilities. These estimates are listed along with the study from 
which they are derived along with the estimated 95% confidence interval. 
Similarly, table 6 shows the corresponding estimated probabilities for facilities 
without onsiteCABG capabilities. The estimate for a door-to-balloon time less 
than ninety minutes for hospitals without open-heart-surgery capabilities is 0.551 
and 95% confidence interval of (0.485 - 0.618), while the corresponding estimate 
for facilities with onsite CABG capabilities is 0.448. 
Table 7 displays the variables that were incorporated in the model. Figure 
1 shows the model along with its corresponding components. From the literature 
review, a key variable for successful PCI outcomes is a door-to-balloon time less 
than 90 minutes. The estimated proportion was estimated to be 55.2% for 
hospitals with onsite CABG 50.0% when both types of facilities were considered. 
The probability of PCI failure for each door-to-balloon cut-off value was 
constituted by the probability of death corresponding to the specific cut-off value 
as well as the probability of complications, which was clearly dependent on the 
door-to-balloon time. This is contrasted with the probabilities for emergency 
CABG; these values did not depend on door-to-balloon time but rather on the 
individual characteristics of the patient. 
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The estimated costs are calculated from a third-party payer point of view 
from public total charges records rather than net payments. Since the latter 
payment is not a public record and considered proprietary information they are 
not available for analysis. For hospitals without onsite CABG capabilities the 
estimated cost for emergency PCI is $48,244 with a standard deviation of 
$26359. In contrast, facilities with onsite CABG capabilities had a mean total 
cost for emergent PCI of $54,675 and a standard deviation of $29,987. 
Cost-Effectiveness 
To evaluate the cost-effectiveness of allowing regional hospitals to 
perform primary PCI the decision model (Figure 1) had to be rolled back. That is, 
the joint probability of each outcome (e.g., DBT < 90 minutes with no adverse 
effects) was multiplied by the utility of the outcome (probability of death) and 
summed over all outcomes; these values were then stratified by alternatives. The 
incremental cost-effectiveness then was evaluated by dividing the incremental 
costs by the incremental effectiveness. 
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Table 12. Estimates for Hospitals with onsite CABG 
Outcome n N 
OTB<90 min 
Thom et al. (47) N/A N/A 
Proportion of BT < 90 min and 95% CI 44.8% 
Mortality when OTB < 90 min 
McNamara et al. (48) 876 29222 
Rat ore et al. ( 4) 909 25359 
Yang et al. (4) 7 479 
Total 1792 55060 
Mortality Rate and 95% CI 3.25% 3.10%-3.40% 
Complications after PCI 
Mattichak et al. (49) 357 7426 
Rate of Complications and 95% CI 4.80% 4.30%-5.30% 
Emergency CABG 
Oarwaza e I. ( ) 31 1200 
Haan at al. (2) 3352 1042864 
Moscucci et al. (3) 49 2303 
Yang et al. (4) 20 6577 
Mattichak e al. (49) 20 7426 
Total 3472 1060370 
Rate of Emergency CABG and 95% CI 0.33% 0.31 %-0.34% 
Mortality after E. CABG 
Oarwaza AK et al. (1) 155 1200 
Haan at al. (2) 536 3352 
Moscucci et al. (3) 10 49 
Yang et al. (4) 2 20 
Seshadri et al. (7) 6 29 
Total 709 4650 
Mortality Rate and 95% CI 15.2% 14.2%-16.3% 
When the cost-effectiveness model was rolled back, the alternative to 
allow Regional Hospitals as well to perform primary PCI dominated the other 
alternative of Only Allowing Hospitals with Onsite CABG to perform PCI. That is, 
allowing regional hospitals to perform primary PCI both incur fewer costs; while 
also averting more deaths (Table 14). Therefore, it "dominates" the other 
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alternative since it performs better on all attributes studied. The incremental cost-
effectiveness ratio of allowing regional hospitals to perform PCI was -$41 K per 
death averted, when compared to the option of Only Hospitals with Onsite CABG 
(Table 14). That is, allowing regional hospitals to perform PCI will save $41 K per 
death averted. Therefore, establishing this alternative as a cost-effectiveness 
way in which to provide primary PCI in the State of Kentucky and providing 
further evidence to allow regional hospitals (that meet the recommendations 
outlined in Myers et al) to perform primary PCI. 
Table 13. Estimates for Hospitals wlo onsite CABG 
Outcome 
DBT <90 min 
Myers et al. 
proportion and 95% CI 
Mortality and DBT < 90 min 
Myers et al. 
K.J. Mishra (1) 
Total 
proportion and 95% CI 
Complications after PCI 
Myers et al. 
proportion and 95% CI 
Emergency CABG 
K.J. Mishra (1) 
Sea Hing Ong et al. (2) 
Myers et al. 
Total 
proportion and 95% CI 
Mortality after E. CABG 
Myers et al. 
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The decision to allow regional hospitals to perform PCI was only sensitive to 
one variable in the model (the cost of PCI at Regional hospitals, cPa). As this cost 
increases, the cost per death averted associated with allowing regional hospitals to 
perform primary PCI also increases making this alternative less attractive. The 
decision is sensitive within the plausible range of values for this variable. If the cost 
of PCI of regional hospitals increases by $5000 (representing a 9.2% increase from 
baseline, from $54,300 to $59,300) allowing regional hospitals to perform primary 
PCI would not be cost effective. 
Table 14. Cost Effectiveness Analysis 
Strategy 
Only Hospitals with onsite CABG 







-$286.19 K 7 -$41,164.25 
Table 15. Model specifications in summary 
Variable Value Variable Value 
RSDBTs 0.448 RLFPa 0.094 
pLDBTs 0.552 pLSPa 0.906 
pSDBTa 0.50 pLPCa 0.574 
pLDBTa pLPMa 0.426 
pM~SDBTs pSESs 0.003 
pM_LDBTs 0.058 pSNEs 0.997 
pM_SDBTa 0.032 pLESs 0.003 
pM_LDBTa , pLNESs 0.997 
pCPCls pSESa 0.003 
pCPCla 0.054 pSNESa 0.997 
pSFPs 0.078 pLESa 0.003 
pSSPs 0.922 pLNESa 0.997 
pSPCs 0.615 pSESSs 0.848 
pSPMs 0.385 pSESFs 0.152 
pLFPs 0.106 pLESSs 0.848 
pLSPs 0.894 pLESFs 0.152 
pLPCs 0.453 pSESSa 0.855 
pLPMs 0.547 pSESFa 0.145 
pSFPa 0.086 pLESSa 0.855 
pSSPa pLESFa 0.145 
pSPCa CPs $54,675 
pSPMa 0.372 CPa $54,389 
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Table 16. Sensitivity Analysis of PCI cost at hospitals with onsite CABG 
CPs Strategy Cost Eff C/E ICER 
54675 Regional Hospitals as Well $54,410 1 $56,450 
Only Hospitals with Onsite CABG $54,686 1 $57,292 (Dominated) 
59645.45 Regional Hospitals as Well $54,543 $56,588 
Only Hospitals with Onsite CABG $59,656 $62,499 (Dominated) 
64615.91 Regional Hospitals as Well $54,677 $56,727 
Only Hospitals with Onsite CABG $64,626 $67,705 (Dominated) 
69586.36 Regional Hospitals as Well $54,811 $56,866 
Only Hospitals with Onsite CABG $69,596 1 $72,912 (Dominated) 
74556.82 Regional Hospitals as Well $54,945 1 $57,005 
Only Hospitals with Onsite CABG $74,565 $78,118 (Dominated) 
79527.27 Regional Hospitals as Well $55,079 $57,144 
Only Hospitals with Onsite CABG $79,535 $83,325 (Dominated) 
84497.73 Regional Hospitals as Well $55,212 1 $57,283 
Only Hospitals with Onsite CABG $84,505 $88,531 (Dominated) 
89468.18 Regional Hospitals as Well $55,346 $57,421 
Only Hospitals with Onsite CABG $89,475 1 $93,738 (Dominated) 
94438.64 Regional Hospitals as Well $55,480 1 $57,560 
Only Hospitals with Onsite CABG $94,444 $98,944 (Dominated) 
99409.09 Regional Hospitals as Well $55,614 $57,699 
Only Hospitals with Onsite CABG $99,414 $104,151 (Dominated) 
Regional Hospitals as Well $57,838 
Only Hospitals with Onsite CABG $104,384 $109,357 (Dominated) 
109350 Regional Hospitals as Well $55,881 1 $57,977 
Only Hospitals with Onsite CABG 1 $114,564 (Dominated) 
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Table 17. Sensitivity Analysis of PCI cost at all hospitals 
CPa Strategy Cost Eff CIE ICER 
54389 Regional Hos itals as Well $54K 0.96 
Only Hospitals with Onsite CABG $55K 0.95 $57,292 (Dominated) 
59333.45 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
$59K 0.96 $61 ,441 $485,435 
64277.90 Onl Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $64K 0.96 $66,431 $1 ,000,518 
69222.36 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $69K 0.96 $71 ,422 $1 ,515,601 
74166.81 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $74K 0.96 $76,413 $2,030,684 
79111 .27 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $78K 0.96 $81,404 $2,545,767 
84055.72 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $83K 0.96 $86,395 $3,060,849 
89000.18 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $88K 0.96 $91,386 $3,575,932 
93944.63 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $93K 0.96 $96,377 $4,091 ,015 
98889.09 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $98K $101,368 $4,606,098 
103833.54 Only Hospitals with Onsite CABG $55K 0.95 $57,292 
Regional Hospitals as Well $103K 0.96 $106,359 $5,121 ,181 
108778 Only Hospitals with Onsite CABG $55K $57,292 
Regional Hospitals as Well $111,350 $5,636,264 
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Table 18. Sensibility Analysis of proportion of DBT<90 min. at hospitals with onsite CABG 
pSDBTs Strategy Cost Eft CtE ICER 
0.298 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,545 (Dominated) 
0.3478333 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,461 (Dominated) 
0.3976666 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,377 (Dominated) 
. 0.4475 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,293 (Dominated) 
0.4973333 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.96 $57,209 (Dominated) 
0.5471666 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.96 $57,126 (Dominated) 
0.597 Regional Hospitals as Well $54.4K 0.96 $56,450 
Only Hospitals with Onsite CABG $54.7K 0.96 $57,043 (Dominated) 
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Table 19. Sensibility Analysis of proportion of DBT<90 min . at all hospitals 
pSDBTa Strategy Cost CIE ICER 
0.33 $56,527 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,292 (Dominated) 
0.385 Regional Hospitals as Well $54.4K 0.96 $56,502 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,292 (Dominated) 
0.44 Regional Hospitals as Well $54.4K 0.96 $56,477 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,292 (Dominated) 
0.495 Regional Hospitals as Well $54.4K 0.96 $56,452 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,292 (Dominated) 
0.55 Regional Hospitals as Well $54.4K 0.96 $56,427 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,292 (Dominated) 
0.605 Regional Hospitals as Well $54.4K 0.96 $56,402 
Only Hospitals with Onsite CABG $54.7K 0.95 $57,292 (Dominated) 
0.66 Regional Hospitals as Well $54.4K 0.97 $56,377 




The current study was based on the results obtained by Myers and his 
colleagues in their report Kentucky Pilot Project for Primary PCI without Onsite 
CABG whose purpose was to investigate whether it was medically sound to allow 
select facilities in Kentucky to perform primary PCI even when lacking onsite 
emergency CABG capabilities. Because the former report established no 
statistically difference in outcomes between facilities with and without open-heart 
surgery backup, this study extended the former report by investigating how cost-
effective it is to allow the latter hospitals to perform emergency PCI given that 
these facilities meet recommendations concerning screening criteria, surgeons' 
experience, and facility's volume (table 1). 
A careful literature review and meta-analysis resulted in robust estimates 
for event rates used in the model. However, the pilot study on which the 
previous report was based did not collect data concerning costs and 
expenditures or related to quality of life of the patients. For this reason, a dataset 
from the National Inpatient Sample 2005 was used to obtain cost estimates. To 
verify that the cost estimated from this data set were relevant, the dataset was 
explored for demographic characteristics using classical numerical and graphical 
statistical methods. The resulting sample from this data set was similar in 
50 
characteristics and outcomes such as age, number of stents used, length of stay, 
and mortality rate to samples used in the literature review studies, meta-analysis, 
and Kentucky pilot study on primary PCI. 
Since the pilot study from which the efficacy data was obtained was 
devoid of costs information, the National Inpatient Sample from 2005 was used to 
obtain estimates of costs from total charges to patients. The reason to use total 
charges as a surrogate to costs is that the latter are considered proprietary 
information to insurance companies; hence, they are not readily available in the 
United States. In addition, costs related to expenditures incurred for 
transportation or incurred by the patient's personal care-giver (e.g. relative or 
spouse) during the hospitalization were not estimated and therefore not included 
in the cost-effectiveness analysis. The time lag between the records of the cost 
data and the clinical trial data is lightly lengthy, and no cost adjustment (Le., 
discounting) was made to evaluate the 2005 currency in 2009 dollars. More 
sophisticated analyses in the future may require a cost-adjustment to estimates 
to 2009 or 2010 dollars, or they may collect cost data and all other variables 
concurrently. Hence, this limitation may undermine the internal validity of the 
results from the cost effectiveness analysis and its associated results. 
The Kentucky Pilot Project for Primary PCI without On site CABG did not 
collect quality of life data from patients or patients' care-giver(s). For this 
reason, the current study was based on cost per death adverted instead. Quality 
of life data from patients such as preference on proximity of the facility providing 
PCI, reduction on door-to-balloon time, and access to primary care provider 
51 
could have increased the cost-effectiveness of allowing facilities without onsite 
CABG capabilities to perform emergent PCI. Also, measurements on preference 
on outcomes such as presence or lack of post-procedure complications, speedier 
recovery given a shorter door-to-balloon time, or even need of quick delivery 
emergent CABG. Furthermore, determining whether delivery of emergent PCI in 
regional hospital rather than transfer to an distant urban facility would facilitate 
access to a loved one, and this in turn could affect the quality of life of the 
patient. 
Another issue at hand when implementing the delivery of emergent PCI at 
regional hospital is the use and allocation of resources in these facilities. This 
study did not measure how this implementation could have affected the allocation 
of resources such as the need to hire more medical staff or the reallocation of 
current medical staff from one unit to another. If the delivery of emergent PCI by 
regional hospitals incurs in the hiring of more medical staff, this could bring about 
economical development to the region surrounding the hospital; however, this 
could also mean an increase in costs of emergent PCI and a possible change in 
the results of this study. Because the recommendations about the quality of care 
include the need that interventional cardiologist in charge of emergent PCI keeps 
a relatively high volume of procedures per year, the chief cardiologist in a 
regional hospital may have to commute several times a month to an urban 
hospital in order to meet the volume recommendations. Another byproduct of 
these recommendations is that possible need to extend PCI delivery to non-
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emergent cases in order to meet facility's volume recommended to keep a highly 
competent medical staff. 
Sensitivity to the cost of PCI at regional hospitals was observed in the 
model. A mere increase of 9.2% or $5,000 from baseline in this variable 
increased the cost per death adverted. This means that the decision is sensitive 
within the plausible range of values for this variable. Consequently, allowing 
regional hospitals to perform primary PCI could become non-cost-effective easily. 
A heart attack or myocardial infarction (MI) is a serious detrimental event 
because deprivation of blood to the heart muscle causes damage or possibly 
death to the heart's tissues known as myocardium, which carry long-term 
negative health conditions. It is been well established that the longer the heart is 
deprived of blood, the more heart muscle is damaged and killed. The maxim 
cardiologists follow is that time saved is heart saved; thus, establishing the need 
to open the coronary arteries occluded as quickly as possible. For this reason a 
short door-to-balloon time is a key aspect for PCI to be successful. Allowing 
regional hospitals to perform emergent PCI is a means to achieve the goal of a 
door-to-balloon time less than ninety minutes for everyone suffering a heart 
attack. Many clinical studies have shown that shorter door-to-balloon time leads 
to shorter average lengths of stay in the hospital, lower rates of reinfarction, and 
lower rates of reocclusion. 
The current study has several implications for the public health policies 
implemented in the state of Kentucky, which must be based on the most current 
evidence. In this case, the latest evidence supports allowing primary PCI to be 
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performed at select facilities without onsite surgical backup. By allowing primary 
PCI to be performed at select facilities without surgical backup, access to PCI 
(the preferred method of reperfusion) is expanded to about forty-four percent of 
the population in the state of Kentucky that are routinely served by these 
facilities. As a result, the state of Kentucky also makes further progress in 
reducing geographical health disparities, one of its main healthcare initiatives. 
Expansion of primary PCI to select facilities without onsite CABG capabilities 
may also increase the proportion of heart attack victims receiving PCI within the 
optimal door-to-balloon time of ninety minutes and thereby improving the quality 
of health outcomes of the population. These facilities are nearer to where the 
patients and their family members live; making their recovery process and time 
more comfortable by having their spouses and loved ones around for comfort 
and support. Similarly, costs associated with visits and transportation will 
decrease as well as costs associated with productivity loss. 
As detailed before in this study, it is well established that PCI is consider 
the superior management strategy for AMI patients, especially those 
experiencing a STEM!. It is also well established that PCI is cost-effective when 
compared to thrombolysis and that it is medically sound to allow hospitals without 
backup surgical capabilities to perform primary PCI. This study had filled the gap 
in the knowledge about the cost-effectiveness of allowing hospitals without 
surgical backup capabilities to perform PCI, when compared to only allowing 
hospitals with backup capabilities to perform PCI in the state of Kentucky. 
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Therefore, the results of this thesis have pushed forward the knowledge 
concerning primary PCI. 
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